about
Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen.Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.Regulatory lymphocytes are key factors in MHC-independent resistance to EAEHsp70 regulates immune response in experimental autoimmune encephalomyelitisNeurofilament light chain level is a weak risk factor for the development of MS.Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation.Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor.Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design.Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis.Myeloid-derived suppressor cells are generated during retroviral transduction of murine bone marrow.Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis.Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02 patients with multiple sclerosisInhibition of delta-like ligand 4 decreases Th1/Th17 response in a mouse model of multiple sclerosisMulti-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosisSemaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosisExpression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions
P50
Q33416725-4CBE1D67-9699-494C-BEC4-CADDA126D649Q33496681-BC472F01-5F26-4539-8226-7D7E085E6675Q33608305-7EF4DDDE-22D2-43FA-BD02-E58534DAE50AQ34083865-A5ED6164-68B8-4C5C-96E6-6FE11F9F37BCQ37265143-84512C51-8A49-482C-8E06-3CF44D71A1EBQ38935150-15164055-C985-43BD-88AC-F81FA738DC07Q39313856-A7475374-6091-48FC-AD7F-8056FC8CB086Q40167890-FF60E848-8C54-4185-8A86-FAD433661A9AQ40190156-B949AC45-C771-416A-8E80-362C28F169BBQ40525363-78B343B1-6758-401A-AE59-8A1544A0E18AQ44829975-A9784889-9D9D-41DD-A42A-E59CBD835C55Q44893711-D009C29F-3207-496E-BBB6-40C995BB9E65Q49388357-971A69F6-E5FD-4B6D-B65B-E94735538E83Q52148517-D9781F78-4805-4053-8913-9A0148B99C1CQ57602119-96238766-754C-4F41-B7D2-7E714BF6E7F8Q58202308-70E5307D-1DAB-45C7-AEBF-28DC2440B334Q58609757-E088796B-7F50-430C-88D1-583BEE0B7F93Q86154088-11148F96-3D37-410D-B89C-604F67E86A94Q90557065-89B18A1C-95CF-4B5E-B846-96A898B4DA9C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Herena Eixarch
@ast
Herena Eixarch
@en
Herena Eixarch
@es
Herena Eixarch
@nl
type
label
Herena Eixarch
@ast
Herena Eixarch
@en
Herena Eixarch
@es
Herena Eixarch
@nl
prefLabel
Herena Eixarch
@ast
Herena Eixarch
@en
Herena Eixarch
@es
Herena Eixarch
@nl
P106
P1153
6508088120
P31
P496
0000-0001-7525-9533